Bluerhexis
Bluerhexis Uses, Dosage, Side Effects, Food Interaction and all others data.
Bluerhexis is a selective tissue staining agent (dye) which stains anterior lens capsule of the human crystalline lens. The dye does not penetrate the capsule, permitting visualization of the anterior capsule in contrast to the non-stained lens cortex and inner lens material.
| Trade Name | Bluerhexis |
| Generic | Trypan Blue |
| Type | Solution |
| Therapeutic Class | Preparations for Ophthalmic diagnosis |
| Manufacturer | Senses Pharmaceuticals Ltd |
| Available Country | India |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Bluerhexis is used for use as an aid in ophthalmic surgery by staining the anterior capsule of the lens.
Dosage
Bluerhexis dosage
The first step to administer Bluerhexis is to inject an air bubble into the anterior chamber using a 26 gauge needle. It prevents dilution of dye by the aqueous humor. Then Bluerhexis is injected into the anterior lens capsule using a tuberculin syringe. Sufficient staining is achieved as soon as the dye has contracted the capsule. If some area is left unstained, inject one more drop till it gets stained.
Side Effects
- Discoloration of high water content hydrogen intraocular lenses.
- Inadvertent staining of the posterior lens capsule and vitreous face.
- It is generally self limited, lasting up to one week.
Precaution
It is recommended that after injection all excess Bluerhexis should be immediately removed from the eye by thorough irrigation of the anterior chamber.
Pregnancy & Breastfeeding use
Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Bluerhexis should be given to a pregnant woman only if the potential benefit justifies the potential risk to the fetus.
Lactation: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Bluerhexis is administered to a nursing woman.
Contraindication
Bluerhexis is contraindicated when a non-hydrated (dry state), hydrophilic acrylic intraocular lens (IOL) is planned to be inserted into the eye because the dye may be absorbed by the IOL and stain the IOL.
Special Warning
Pediatric use: The safety and effectiveness of Bluerhexis have been established in pediatric patients. Use of Bluerhexis is supported by evidence from an adequate and well controlled study in pediatric patients.
Geriatric use: No overall differences in safety and effectiveness have been observed between elderly and younger patients.
Storage Condition
Store below 30° C and keep away from light.
Innovators Monograph
You find simplified version here Bluerhexis
FAQ
What is Bluerhexis used for?
Bluerhexis is a diazo dye that has been widely used to color dead tissues or cells selectively.The mechanism of trypan blue staining is based on it being negatively charged and not interacting with cells unless the membrane is damaged.
How safe is Bluerhexis?
Bluerhexis may cause cancer, genetic defects, and damage fertility, or cause harm to an unborn child.Special precautions should be taken to avoid exposing operators to trypan blue whilst working with and disposing of the dye.
What are the common side effects of Bluerhexis?
Common side effects of Bluerhexis include: temporary blue coloration of the eye, and staining of implanted lenses.
Is Bluerhexis safe during pregnancy?
This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus.
Is Bluerhexis safe during breastfeeding?
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when trypan blue is administered to a nursing woman.
How does Bluerhexis work?
Bluerhexis binds to intracellular proteins and render the cells a blue color.
Why is Bluerhexis used in cataract surgery?
Bluerhexis is the most frequently used in cataract surgery due to its safety, availability and effectiveness.
Is Bluerhexis toxic to humans?
Bluerhexis is not toxic, in terms of cell viability, over an exposure time of up to 60s; however, further exposure results in a gradual increase in damage of cultured human trabecular meshwork cells.
